Compare Incyte Corporation (INCY) vs Johnson Controls International PLC (JCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Johnson Controls International PLC — how do they compare? Incyte Corporation trades at $117 (market cap $23.11B), while Johnson Controls International PLC trades at $140 (market cap $85.03B). The key difference: Johnson Controls International PLC is far larger — about 3.7× Incyte Corporation's market cap, and Johnson Controls International PLC pays a 1.15% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | JCI | |
|---|---|---|
Market Cap | $23.11B | $85.03B |
Sector | Health | Industrials |
52-Week High | $118.52 | $148.21 |
52-Week Low | $67.38 | $103.24 |
Enterprise Value | $19.13B | $93.86B |
Dividend Yield | — | 1.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $117.39, up 0.12% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $112.78. The company reported strong Q1 2026 earnings of $1.81 per share, beating expectations, and maintains robust profitability with a net income margin of 26.71%. Recent developments include a collaboration with Halozyme for cancer therapy and positive regulatory updates for Opzelura in Europe.
Outlook remains positive driven by earnings growth and pipeline advancements, though risks include competitive pressures and reliance on key products. The stock offers potential upside to the high target of $140, supported by institutional interest and solid cash flow generation, but investors should monitor execution on upcoming Q2 results.
Johnson Controls International (JCI) trades at $141.71, up 0.89% with a bearish technical signal but strong analyst support. Recent earnings beats and a 14.45% net margin highlight operational strength, while valuation metrics like a P/E of 42.62 suggest premium pricing. The company maintains a dividend and benefits from positive news flow, including industry awards and strategic appointments.
Outlook is mixed: bullish fundamentals and analyst consensus target of $158.29 offer upside, but technical weakness and high valuation pose risks. Key drivers include execution in building systems and data center demand, while debt levels and economic sensitivity require monitoring for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →
